ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets

ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes

• AdoShell Islets regulated glycemic control in immunocompetent diabetic animals in a 132-day trial without the use of insulin or immunosuppression.
• These results will be presented at the upcoming cell therapy session of the PODD 2022 conference held in Boston in October.
• A new series of diabetic rats, being treated with AdoShell Islets, confirm these promising results with 80 days normoglycemia.
• AdoShell Islets will be evaluated in diabetic pigs in the 4th quarter of 2022.

READ THE PRESS RELEASE